Wuqing Wang

Dr. Wuqing Wang

Fudan Univeristy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HWHui Wang
Hui Wang
YCYuxin Chen
Yuxin Chen
JLJun Lv
Jun Lv
XCXiaoting Cheng
Xiaoting Cheng
QCQi Cao
Qi Cao
YSYilai Shu
Yilai Shu
Gene therapy is a promising approach for hereditary deafness. We recently showed that unilateral AAV1-hOTOF gene therapy with dual adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and associated with functional improvements in patients with autosomal recessive deafness 9 (DFNB9). The protocol was subsequently amended and approved to allow bilateral gene therapy administration. Here we report an interim analysis of the single-arm trial investigating the safety and efficacy of binaural therapy in five pediatric patients with DFNB9. The primary endpoint was dose-limiting toxicity at 6 weeks, and the secondary endpoint included safety (adverse events) and efficacy (auditory function and speech perception). No dose-limiting toxicity or serious adverse event occurred. A total of 36 adverse events occurred. The most common adverse events were increased lymphocyte counts (6 out of 36) and increased cholesterol levels (6 out of 36). All patients had bilateral hearing restoration. The average auditory brainstem response threshold in the right (left) ear was >95 dB (>95 dB) in all patients at baseline, and the average auditory brainstem response threshold in the right (left) ear was restored to 58 dB (58 dB) in patient 1, 75 dB (85 dB) in patient 2, 55 dB (50 dB) in patient 3 at 26 weeks, and 75 dB (78 dB) in patient 4 and 63 dB (63 dB) in patient 5 at 13 weeks. The speech perception and the capability of sound source localization were restored in all five patients. These results provide preliminary insights on the safety and efficacy of binaural AAV gene therapy for hereditary deafness. The trial is ongoing with longer follow-up to confirm the safety and efficacy findings. Chinese Clinical Trial Registry registration: ChiCTR2200063181.

16 November 2022 in Human Genetics
Verified
Journal Article
Closed access
PDF file
HTHonghai Tang
Honghai Tang
HWHui Wang
Hui Wang
SWShengyi Wang
Shengyi Wang
SHShao Wei Hu
Shao Wei Hu
JLJun Lv
Jun Lv
YSYilai Shu
Yilai Shu

21 February 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
WSWenfang Sun
Wenfang Sun
PGPing Guo
Ping Guo
TRTongli Ren
Tongli Ren
WWWuqing Wang
Wuqing Wang

15 July 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
SSSuming Shi
Suming Shi
DWDan Wang
Dan Wang
TRTongli Ren
Tongli Ren
WWWuqing Wang
Wuqing Wang
Objectives: To investigate the auditory features of patients with vestibular migraine (VM) and to analyze the possible relevant factors of hearing loss.Methods: A total of 166 patients with VM were enrolled. Demographic variables, age of onset, disease course, distribution of vestibular attacks, characteristics of hearing loss, and the coexistence of related disorders, such as visual aura, familial history, motion sickness, nausea, headache, photophobia, otalgia, tinnitus, aural fullness, and phonophobia, were analyzed and compared.Results: Patients with VM can manifest otalgia (8.4%), tinnitus (51.8%), aural fullness (41%), and phonophobia (31.9%). Of 166 patients, the prevalence of VMw was 21.1% (n = 35). Patients with VMw mainly manifested mild and easily reversible low-frequency hearing loss. The proportions of tinnitus and aural fullness were significantly larger in patients with VMw than that in patients with VMo (P < 0.05). The duration of vestibular symptoms was significantly shorter in patients with VMw (P < 0.05). However, the age of onset, disease course, gender, frequency of vestibular attacks, the coexistence of visual aura, familial history, motion sickness, nausea, headache, photophobia, otalgia, and phonophobia had no significant difference between the two groups.Conclusion: Auditory symptoms were common in patients with VM. The hearing loss of VM was characterized by a mild and easily reversible low-frequency hearing loss, accompanied by higher proportions of tinnitus and aural fullness, and a shorter duration of vestibular symptoms compared with patients with VMo.

2 February 2024 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
HWHui Wang
Hui Wang
MXMengZhao Xun
MengZhao Xun
HTHonghai Tang
Honghai Tang
JZJingjing Zhao
Jingjing Zhao
SHShaowei Hu
Shaowei Hu
HLHuawei Li
Huawei Li
Adeno-associated viral (AAV) vectors are increasingly used as vehicles for gene delivery to treat hearing loss. However, lack of specificity of the transgene expression may lead to overexpression of the transgene in nontarget tissues. In this study, we evaluated the expression efficiency and specificity of transgene delivered by AAV-PHP.eB under the inner ear sensory cell-specific Myo15 promoter. Compared with the ubiquitous CAG promoter, the Myo15 promoter initiates efficient expression of the GFP fluorescence reporter in hair cells, while minimizing non-specific expression in other cell types of the inner ear and CNS. Furthermore, using the Myo15 promoter, we constructed an AAV-mediated therapeutic system with the coding sequence of OTOF gene. After inner ear injection, we observed apparent hearing recovery in Otof-/- mice, highly efficient expression of exogenous otoferlin, and significant improvement in the exocytosis function of inner hair cells. Overall, our results indicate that gene therapy mediated by the hair cell-specific Myo15 promoter has potential clinical application for the treatment of autosomal recessive deafness and yet for other hereditary hearing loss related to dysfunction of hair cells.

1 January 2015 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
PGPing Guo
Ping Guo
WWWuqing Wang
Wuqing Wang
Guo P, et al. Clin Exp Otorhinolaryngol. 2015 Jun;8(2):111-116. http://dx.doi.org/10.3342/ceo.2015.8.2.111